Prospective randomized trial of empiric therapy with trimethoprim- sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus

Mary Jo Cenizal, Daniel Skiest, Samuel Luber, Roger Bedimo, Pat Davis, Patrick Fox, Kathleen Delaney, R. Doug Hardy

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

To evaluate empirical therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, a randomized, prospective, open-label investigation was performed. The overall clinical failure rate was 9%, with all failures occurring in the trimethoprim- sulfamethoxazole group. However, there was no significant difference between the clinical failure rate of empirical trimethoprim-sulfamethoxazole therapy and that of doxycycline therapy.

Original languageEnglish (US)
Pages (from-to)2628-2630
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume51
Issue number7
DOIs
StatePublished - Jul 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prospective randomized trial of empiric therapy with trimethoprim- sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus'. Together they form a unique fingerprint.

Cite this